Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,103 active trials29 approved drugs653 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07232290 | Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera | recruiting | Phase 2 | 60 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07384039 | Exercise Training in Patients With Myeloproliferative Neoplasms(MPN-Exercise) | recruiting | N/A | 80 | Hannover Medical SchoolOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07761533 | PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS | recruiting | Phase 1 / Phase 2 | 29 | Chaser Therapeutics, Inc.INDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT01728402 | Pathogenesis of Hematologic Malignancies | enrolling by invitation | — | 5,000 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT01784068 | Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients(ENESTfreedom) | completed | Phase 2 | 215 | Novartis PharmaceuticalsINDUSTRY | 19 | Aug 13, 2026 | clinicaltrials |
| NCT02577926 | The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia(Ruxo-BEAT) | active not recruiting | Phase 2 | 207 | RWTH Aachen UniversityOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02732184 | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS | completed | Phase 1 | 21 | Immedica Pharma ABINDUSTRY | 2 | Aug 13, 2026 | clinicaltrials |
| NCT03737955 | Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia | recruiting | Phase 2 | 36 | University of WashingtonOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05115344 | Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors | withdrawn | Phase 1 | 0 | Guizhou Bailing Group Pharmaceutical Co LtdINDUSTRY | 0 | Aug 13, 2026 | clinicaltrials |
| NCT06468033 | P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | active not recruiting | Phase 3 | 160 | PharmaEssentiaINDUSTRY | 9 | Aug 13, 2026 | clinicaltrials |
| NCT07469592 | eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation | recruiting | N/A | 165 | University of MiamiOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07570407 | Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation(QiNKT-HSCT) | recruiting | — | 75 | University Hospital PilsenOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07570823 | A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 3 | 101 | Sinocelltech Ltd.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07763054 | Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients | recruiting | — | 30 | Haikou Affiliated Hospital of Central South University Xiangya School of MedicineOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT01698905 | Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)(ENESTop) | completed | Phase 2 | 163 | Novartis PharmaceuticalsINDUSTRY | 18 | Aug 12, 2026 | clinicaltrials |
| NCT02942290 | A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS) | completed | Phase 1 | 134 | AbbVieINDUSTRY | 7 | Aug 12, 2026 | clinicaltrials |
| NCT03680677 | Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies | recruiting | — | 20 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05188170 | Niclosamide in Pediatric Patients With Relapsed and Refractory AML | recruiting | Phase 1 | 16 | Stanford UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05444348 | Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)(ACT) | recruiting | N/A | 920 | Christoffer JohansenOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05968963 | Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation | completed | N/A | 61 | University of MiamiOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06313593 | A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms | active not recruiting | Phase 1 | 37 | Incyte CorporationINDUSTRY | 8 | Aug 12, 2026 | clinicaltrials |
| NCT07761702 | Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML | not yet recruiting | Phase 3 | 132 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Aug 12, 2026 | clinicaltrials |
| NCT04708054 | Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | recruiting | Phase 2 / Phase 3 | 324 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04827719 | BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS | completed | Phase 2 | 38 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05457010 | Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS | active not recruiting | Phase 1 | 24 | Arcellx, Inc.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06159491 | Pacritinib in CMML | recruiting | Phase 1 / Phase 2 | 26 | Douglas TremblayOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07486713 | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies | recruiting | Phase 4 | 16 | Rigel PharmaceuticalsINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07758218 | Allogeneic iNKT Cell Therapy (agenT-797) After SCT | not yet recruiting | Phase 1 | 22 | University of Wisconsin, MadisonOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT00935090 | 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer | active not recruiting | — | — | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03503409 | IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome | active not recruiting | Phase 2 | 68 | Groupe Francophone des MyelodysplasiesOTHER | 2 | Aug 10, 2026 | clinicaltrials |
| NCT03744390 | IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome | active not recruiting | Phase 2 | 68 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05308264 | Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | recruiting | Phase 1 / Phase 2 | 86 | Rigel PharmaceuticalsINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05936359 | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | active not recruiting | Phase 1 | 160 | Incyte CorporationINDUSTRY | 9 | Aug 10, 2026 | clinicaltrials |
| NCT06285890 | Phase I Study of HC-7366 for Acute Myeloid Leukemia | recruiting | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06361641 | Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes(PHEMOP) | recruiting | N/A | 70 | University Hospital, AngersOTHER_GOV | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06390319 | Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) | recruiting | Phase 2 | 100 | St. Jude Children's Research HospitalOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06492707 | DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial | suspended | Phase 1 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06529250 | Intermediate-dose HAD Regimen for CEBPA Double-mutated AML(HADCEBPA2023) | recruiting | N/A | 148 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07131059 | MRD-positive AML Clinical Study | recruiting | N/A | 537 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07681258 | A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region(ASC4Young) | not yet recruiting | — | 80 | Novartis PharmaceuticalsINDUSTRY | 0 | Aug 10, 2026 | clinicaltrials |
| NCT07755202 | Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia(GAVE001) | not yet recruiting | Phase 2 | 20 | Florian KuchenbauerOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07756034 | Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer(ONCO-OLIVIA) | recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT00392353 | Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 135 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2026 | clinicaltrials |
| NCT02071901 | Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy | completed | Phase 2 | 31 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT03573024 | Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia | completed | Phase 2 | 36 | University of Colorado, DenverOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05092451 | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances | recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06265545 | Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia | recruiting | N/A | 458 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06744504 | Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 | recruiting | Phase 3 | 284 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07061145 | A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia(ED2024) | recruiting | — | 350 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Aug 7, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 14, 2026source: clinicaltrials